This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Utility of flow cytometry screening before MRD testing in multiple myeloma
Blood Cancer Journal Open Access 20 April 2023
-
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
Blood Cancer Journal Open Access 25 February 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
San Miguel JF, Almeida J, Mateo G, Blade J, Lopez-Berges C, Caballero D et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002; 99: 1853–1856.
Sarasquete ME, Garcia-Sanz R, Gonzalez D, Martinez J, Mateo G, Martinez P et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005; 90: 1365–1372.
Greipp PR, Kumar S . Plasma cell labeling index. Methods Mol Med 2005; 113: 25–35.
Lin P, Owens R, Tricot G, Wilson CS . Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482–488.
Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros LJ . Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol 2005; 123: 200–205.
Bataille R, Robillard N, Pellat-Deceunynck C, Amiot M . A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev 2003; 194: 105–111.
Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE . Cd45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 2005; 19: 1466–1470.
Rawstron AC, Barrans SL, Blythe D, English A, Richards SJ, Fenton JA et al. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by vla-5 and CD45 expression. Br J Haematol 2001; 113: 794–802.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morice, W., Hanson, C., Kumar, S. et al. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia 21, 2043–2046 (2007). https://doi.org/10.1038/sj.leu.2404712
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404712
This article is cited by
-
Utility of flow cytometry screening before MRD testing in multiple myeloma
Blood Cancer Journal (2023)
-
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
Blood Cancer Journal (2020)
-
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis
Leukemia (2018)
-
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
Leukemia (2014)
-
The current status of minimal residual disease assessment in myeloma
Leukemia (2014)